217 related articles for article (PubMed ID: 26988247)
1. Precision Medicine for Diffuse Large B-cell Lymphoma.
Lim MS; Elenitoba-Johnson KS
Clin Cancer Res; 2016 Jun; 22(12):2829-31. PubMed ID: 26988247
[TBL] [Abstract][Full Text] [Related]
2. Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study.
Dubois S; Viailly PJ; Mareschal S; Bohers E; Bertrand P; Ruminy P; Maingonnat C; Jais JP; Peyrouze P; Figeac M; Molina TJ; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Brière J; Petrella T; Canioni D; Fabiani B; Coiffier B; Delarue R; Peyrade F; Bosly A; André M; Ketterer N; Salles G; Tilly H; Leroy K; Jardin F
Clin Cancer Res; 2016 Jun; 22(12):2919-28. PubMed ID: 26819451
[TBL] [Abstract][Full Text] [Related]
3. Primary central nervous system lymphoma: Novel precision therapies.
Mondello P; Mian M; Bertoni F
Crit Rev Oncol Hematol; 2019 Sep; 141():139-145. PubMed ID: 31295667
[TBL] [Abstract][Full Text] [Related]
4. The role of next-generation sequencing in understanding the genomic basis of diffuse large B cell lymphoma and advancing targeted therapies.
Dubois S; Jardin F
Expert Rev Hematol; 2016 Mar; 9(3):255-69. PubMed ID: 26652775
[TBL] [Abstract][Full Text] [Related]
5. Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma: Genetic Classification and Its Implications for Prognosis and Treatment.
Crombie JL; Armand P
Hematol Oncol Clin North Am; 2019 Aug; 33(4):575-585. PubMed ID: 31229155
[TBL] [Abstract][Full Text] [Related]
6. Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma: Genetic Classification and Its Implications for Prognosis and Treatment.
Crombie JL; Armand P
Surg Oncol Clin N Am; 2020 Jan; 29(1):115-125. PubMed ID: 31757308
[TBL] [Abstract][Full Text] [Related]
7. Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era.
Bohers E; Mareschal S; Bertrand P; Viailly PJ; Dubois S; Maingonnat C; Ruminy P; Tilly H; Jardin F
Leuk Lymphoma; 2015 May; 56(5):1213-22. PubMed ID: 25130477
[TBL] [Abstract][Full Text] [Related]
8. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
Coyne GO; Takebe N; Chen AP
Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823
[TBL] [Abstract][Full Text] [Related]
9. The molecular background of aggressive B cell lymphomas as a basis for targeted therapy.
de Jong D; Balagué Ponz O
J Pathol; 2011 Jan; 223(2):274-82. PubMed ID: 21125680
[TBL] [Abstract][Full Text] [Related]
10. Advances in the molecular diagnosis of diffuse large B-cell lymphoma in the era of precision medicine.
Araf S; Korfi K; Rahim T; Davies A; Fitzgibbon J
Expert Rev Mol Diagn; 2016 Oct; 16(10):1093-1102. PubMed ID: 27648481
[TBL] [Abstract][Full Text] [Related]
11. Toward a New Molecular Taxonomy of Diffuse Large B-cell Lymphoma.
Ennishi D; Hsi ED; Steidl C; Scott DW
Cancer Discov; 2020 Sep; 10(9):1267-1281. PubMed ID: 32616477
[TBL] [Abstract][Full Text] [Related]
12. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
Albin N; Mc Leer A; Sakhri L
Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
[TBL] [Abstract][Full Text] [Related]
13. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
Camicia R; Winkler HC; Hassa PO
Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
[TBL] [Abstract][Full Text] [Related]
14. All roads lead to targeted diffuse large B-cell lymphoma approaches.
Xu PP; Huo YJ; Zhao WL
Cancer Cell; 2022 Feb; 40(2):131-133. PubMed ID: 35167823
[TBL] [Abstract][Full Text] [Related]
15. Diffuse large B-cell lymphoma with MYC gene rearrangements: Current perspective on treatment of diffuse large B-cell lymphoma with MYC gene rearrangements; case series and review of the literature.
de Jonge AV; Roosma TJ; Houtenbos I; Vasmel WL; van de Hem K; de Boer JP; van Maanen T; Lindauer-van der Werf G; Beeker A; Timmers GJ; Schaar CG; Soesan M; Poddighe PJ; de Jong D; Chamuleau ME
Eur J Cancer; 2016 Mar; 55():140-6. PubMed ID: 26820684
[TBL] [Abstract][Full Text] [Related]
16. Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study.
Worst BC; van Tilburg CM; Balasubramanian GP; Fiesel P; Witt R; Freitag A; Boudalil M; Previti C; Wolf S; Schmidt S; Chotewutmontri S; Bewerunge-Hudler M; Schick M; Schlesner M; Hutter B; Taylor L; Borst T; Sutter C; Bartram CR; Milde T; Pfaff E; Kulozik AE; von Stackelberg A; Meisel R; Borkhardt A; Reinhardt D; Klusmann JH; Fleischhack G; Tippelt S; Dirksen U; Jürgens H; Kramm CM; von Bueren AO; Westermann F; Fischer M; Burkhardt B; Wößmann W; Nathrath M; Bielack SS; Frühwald MC; Fulda S; Klingebiel T; Koscielniak E; Schwab M; Tremmel R; Driever PH; Schulte JH; Brors B; von Deimling A; Lichter P; Eggert A; Capper D; Pfister SM; Jones DT; Witt O
Eur J Cancer; 2016 Sep; 65():91-101. PubMed ID: 27479119
[TBL] [Abstract][Full Text] [Related]
17. Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision Therapy.
Karmali R; Gordon LI
Curr Treat Options Oncol; 2017 Feb; 18(2):11. PubMed ID: 28229364
[TBL] [Abstract][Full Text] [Related]
18. Emerging drugs for diffuse large B-cell lymphoma.
Mondello P; Younes A
Expert Rev Anticancer Ther; 2015 Apr; 15(4):439-51. PubMed ID: 25652253
[TBL] [Abstract][Full Text] [Related]
19. [Diffuse Large B cell Lymphoma - Modern Dia-gnostics and Molecularly Targeted Treatment].
Pytlík R; Trněný M
Klin Onkol; 2015; 28 Suppl 3():3S64-72. PubMed ID: 26489504
[TBL] [Abstract][Full Text] [Related]
20. Precision medicine in diffuse large B-cell lymphoma: hitting the target.
Vermaat JS; Pals ST; Younes A; Dreyling M; Federico M; Aurer I; Radford J; Kersten MJ;
Haematologica; 2015 Aug; 100(8):989-93. PubMed ID: 26314080
[No Abstract] [Full Text] [Related]
[Next] [New Search]
